adplus-dvertising
Connect with us

Business

FDA approves updated Pfizer, Moderna COVID vaccines: Here is what to know

Published

 on

The US has authorised updated COVID vaccines that target a recently circulating Omicron variant.

The United States Food and Drug Administration (FDA) has approved updated COVID-19 vaccines, hoping to increase protection against the latest coronavirus strains and blunt any surge in the upcoming autumn and winter seasons in the northern hemisphere.

Here is what you need to know about the vaccines and their effectiveness:

Why do we have more COVID-19 vaccines?

The evolving coronavirus is not going away. Similar to how flu shots are updated each year, the FDA has told COVID vaccine manufacturers what the focus should be.

The updated vaccine shots had a single target: an Omicron descendant named XBB.1.5.

It is a big change as the vaccines offered since last year are combination shots targeting the original coronavirus strain and its Omicron variant detected much before the XBB.1.5, making them very outdated.

The FDA has approved the new vaccines by Pfizer and Moderna, while the Novarax version is still under review.

The authorisation also follows a recent rise in cases that came at a time when the new EG.5 subvariant of Omicron – nicknamed Eris – has begun to spread rapidly in the US and other countries.

Scientists have also raised concerns about the highly mutated BA.2.86 subvariant that has been detected in several countries.

When will the new COVID vaccines be available?

Pfizer and Moderna said their updated vaccines were expected to be available for most people in the US in the coming days.

An endorsement by Centers for Disease Control and Prevention (CDC) Director Mandy Cohen, expected in the coming days, should clear the way for the new shots. Cohen has said she expects the shots to roll out in September.

Who should get the new coronavirus vaccine?

The FDA has approved the shots for people ages 12 and above and authorised them for emergency use in children ages six months to 11 years.

Will they be effective enough?

Health officials are optimistic, barring a new virus mutation.

The XBB.1.5 variant has faded away in the months it took to tweak the vaccine. Today, there is a mix of different variants causing illness, and the most common ones are fairly close relatives.

Recent lab testing from vaccine makers and other research groups suggests the updated shots will offer crossover protection.

Earlier vaccinations or infections have continued to help prevent severe disease and death, but protection wanes over time, especially against milder infections, as the virus continually evolves.

Like earlier versions, they are expected to be most protective against COVID’s worst consequences rather than mild infection.

Can you get flu and COVID-19 shots at the same time?

Yes. The CDC says there is no difference in effectiveness or side effects if people get the shots simultaneously, although one in each arm might be more comfortable.

The CDC urges an annual flu shot for pretty much everyone aged six months and above.

 

728x90x4

Source link

Continue Reading

Business

Cineplex reports $24.7M Q3 loss on Competition Tribunal penalty

Published

 on

 

TORONTO – Cineplex Inc. reported a loss in its latest quarter compared with a profit a year ago as it was hit by a fine for deceptive marketing practices imposed by the Competition Tribunal.

The movie theatre company says it lost $24.7 million or 39 cents per diluted share for the quarter ended Sept. 30 compared with a profit of $29.7 million or 40 cents per diluted share a year earlier.

The results in the most recent quarter included a $39.2-million provision related to the Competition Tribunal decision, which Cineplex is appealing.

The Competition Bureau accused the company of misleading theatregoers by not immediately presenting them with the full price of a movie ticket when they purchased seats online, a view the company has rejected.

Revenue for the quarter totalled $395.6 million, down from $414.5 million in the same quarter last year, while theatre attendance totalled 13.3 million for the quarter compared with nearly 15.7 million a year earlier.

Box office revenue per patron in the quarter climbed to $13.19 compared with $12 in the same quarter last year, while concession revenue per patron amounted to $9.85, up from $8.44 a year ago.

This report by The Canadian Press was first published Nov. 6, 2024.

Companies in this story: (TSX:CGX)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Restaurant Brands reports US$357M Q3 net income, down from US$364M a year ago

Published

 on

 

TORONTO – Restaurant Brands International Inc. reported net income of US$357 million for its third quarter, down from US$364 million in the same quarter last year.

The company, which keeps its books in U.S. dollars, says its profit amounted to 79 cents US per diluted share for the quarter ended Sept. 30 compared with 79 cents US per diluted share a year earlier.

Revenue for the parent company of Tim Hortons, Burger King, Popeyes and Firehouse Subs, totalled US$2.29 billion, up from US$1.84 billion in the same quarter last year.

Consolidated comparable sales were up 0.3 per cent.

On an adjusted basis, Restaurant Brands says it earned 93 cents US per diluted share in its latest quarter, up from an adjusted profit of 90 cents US per diluted share a year earlier.

The average analyst estimate had been for a profit of 95 cents US per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 5, 2024.

Companies in this story: (TSX:QSR)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Electric and gas utility Fortis reports $420M Q3 profit, up from $394M a year ago

Published

 on

 

ST. JOHN’S, N.L. – Fortis Inc. reported a third-quarter profit of $420 million, up from $394 million in the same quarter last year.

The electric and gas utility says the profit amounted to 85 cents per share for the quarter ended Sept. 30, up from 81 cents per share a year earlier.

Fortis says the increase was driven by rate base growth across its utilities, and strong earnings in Arizona largely reflecting new customer rates at Tucson Electric Power.

Revenue in the quarter totalled $2.77 billion, up from $2.72 billion in the same quarter last year.

On an adjusted basis, Fortis says it earned 85 cents per share in its latest quarter, up from an adjusted profit of 84 cents per share in the third quarter of 2023.

The average analyst estimate had been for a profit of 82 cents per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 5, 2024.

Companies in this story: (TSX:FTS)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending